title: Immunotherapy's cancer remit widens.
authors.forename: Heidi
authors.initials: H
authors.lastname: Ledford
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination / Q000706:statistics & numerical data*; D006801:Humans; D007167:Immunotherapy / Q000706:statistics & numerical data*; D000074324:Ipilimumab; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy / Q000628:therapy*; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000077594:Nivolumab